🇺🇸 OXYTETRACYCLINE CALCIUM in United States

14 US adverse-event reports

Marketing authorisations

FDA

  • Status: approved

FDA

  • Application: ANDA060595
  • Marketing authorisation holder: PFIZER
  • Local brand name: TERRAMYCIN
  • Indication: SYRUP — ORAL
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dizziness — 3 reports (21.43%)
  2. Cystitis — 2 reports (14.29%)
  3. Dyspnoea — 2 reports (14.29%)
  4. Abdominal Pain Upper — 1 report (7.14%)
  5. Abscess Sterile — 1 report (7.14%)
  6. Acute Kidney Injury — 1 report (7.14%)
  7. Alopecia — 1 report (7.14%)
  8. Anaemia — 1 report (7.14%)
  9. Anxiety — 1 report (7.14%)
  10. Arrhythmia — 1 report (7.14%)

Source database →

OXYTETRACYCLINE CALCIUM in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is OXYTETRACYCLINE CALCIUM approved in United States?

Yes. FDA has authorised it; FDA has authorised it.

Who is the marketing authorisation holder for OXYTETRACYCLINE CALCIUM in United States?

Marketing authorisation holder not available in our data.